Lower-Risk MDS: A Review of Data from the ASH 2022 Annual Meeting

home / the-talk / lower-risk-mds-a-review-of-data-from-the-ash-2022-annual-meeting

Experts in hematologic oncology give an overview of first- and second-line MDS treatment options, and discuss updates from the ASH 2022 Annual Meeting.

Experts on myelodysplastic syndromes

EP. 1: First- and Second-Line Treatment Options in Lower-Risk MDS

February 24th 2023

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Experts on myelodysplastic syndromes

EP. 2: Luspatercept in Lower-Risk MDS

February 24th 2023

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

Experts on myelodysplastic syndromes

EP. 3: Emerging Therapies for Lower-Risk MDS

February 24th 2023

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.